Subspecialties Oncology, Screening and monitoring, Precision medicine

Exploring MSI Screening Technologies

12/14/2020

sponsored by Promega

December 14th 2020, 2pm GMT

Microsatellite Instability (MSI)-High has been identified as a biomarker for immune checkpoint inhibitor therapy in cancers originating in different tissues. As such, key opinion leaders have recommended MSI screening across all solid tumors. This Webinar will explore the biology of MSI; latest clinical practice guidelines around MSI screening; and a new tool to assess MSI status in Europe: the Promega OncoMate™ MSI Dx Analysis System, a PCR-based, validated gold standard for MSI status detection that provides analytical sensitivity and unsurpassed specificity with a short turn-around time.

Webinar Learning Objectives:

Discuss the biology of microsatellite instability (MSI), including the relation between MMR protein dysfunction and MSI
Provide overview of latest clinical practice guidelines regarding MSI screening in relevant tumor types
Introduce Promega OncoMate™ MSI Dx Analysis System, a PCR-based, validated gold standard for MSI status detection in Europe

Available On-Demand

Visit our Webinar Hub

Email*

Choose a password

I have read and understand the Privacy Notice *

Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

I want to stay up to date with the Infectious Diseases field I want to stay up to date with the Pathologist Educator field

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.